Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016
ReportsWeb.com has announced the addition of the “Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016” this report provides an overview of the Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline landscape.
(EMAILWIRE.COM, June 23, 2017 ) Muscle-invasive disease is a type of bladder cancer which is much more likely to spread to other parts of the body Symptoms includes blood in the urine and pain when passing urine. Risk factors include use of tobacco, family history, exposure to arsenic, and infections. Treatment includes removing the bladder or treating the bladder with radiation and chemotherapy.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Muscle Invasive Bladder Cancer (MIBC) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Muscle Invasive Bladder Cancer (MIBC) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 4, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Muscle Invasive Bladder Cancer (MIBC).
Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/muscle-invasive-bladder-cancer-mibc-pipeline-review-h2-2016
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Muscle Invasive Bladder Cancer (MIBC) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Muscle Invasive Bladder Cancer (MIBC) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Muscle Invasive Bladder Cancer (MIBC) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Muscle Invasive Bladder Cancer (MIBC) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Muscle Invasive Bladder Cancer (MIBC) (Oncology)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001492636/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Muscle Invasive Bladder Cancer (MIBC) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Argos Therapeutics Inc
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Cold Genesys Inc
F. Hoffmann-La Roche Ltd
MedImmune LLC
Oncolytics Biotech Inc
Sillajen Biotherapeutics
Taris Biomedical LLC
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001492636/discount
List of Tables
Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC), H2 2016 8
Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC) - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Argos Therapeutics Inc, H2 2016 17
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Astellas Pharma Inc, H2 2016 18
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Astex Pharmaceuticals Inc, H2 2016 19
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by AstraZeneca Plc, H2 2016 20
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Cold Genesys Inc, H2 2016 21
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 22
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by MedImmune LLC, H2 2016 23
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Oncolytics Biotech Inc, H2 2016 24
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Sillajen Biotherapeutics, H2 2016 25
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Taris Biomedical LLC, H2 2016 26
Assessment by Monotherapy Products, H2 2016 27
Assessment by Combination Products, H2 2016 28
Number of Products by Stage and Target, H2 2016 30
Number of Products by Stage and Mechanism of Action, H2 2016 32
Number of Products by Stage and Route of Administration, H2 2016 34
Number of Products by Stage and Molecule Type, H2 2016 36
Muscle Invasive Bladder Cancer (MIBC) - Dormant Projects, H2 2016 104Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC), H2 2016 8
Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC) - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Argos Therapeutics Inc, H2 2016 17
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Astellas Pharma Inc, H2 2016 18
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Astex Pharmaceuticals Inc, H2 2016 19
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by AstraZeneca Plc, H2 2016 20
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Cold Genesys Inc, H2 2016 21
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 22
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by MedImmune LLC, H2 2016 23
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Oncolytics Biotech Inc, H2 2016 24
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Sillajen Biotherapeutics, H2 2016 25
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Taris Biomedical LLC, H2 2016 26
Assessment by Monotherapy Products, H2 2016 27
Assessment by Combination Products, H2 2016 28
Number of Products by Stage and Target, H2 2016 30
Number of Products by Stage and Mechanism of Action, H2 2016 32
Number of Products by Stage and Route of Administration, H2 2016 34
Number of Products by Stage and Molecule Type, H2 2016 36
Muscle Invasive Bladder Cancer (MIBC) - Dormant Projects, H2 2016 104
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001492636/buy/2000
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Muscle Invasive Bladder Cancer (MIBC) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Muscle Invasive Bladder Cancer (MIBC) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 4, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Muscle Invasive Bladder Cancer (MIBC).
Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/muscle-invasive-bladder-cancer-mibc-pipeline-review-h2-2016
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Muscle Invasive Bladder Cancer (MIBC) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Muscle Invasive Bladder Cancer (MIBC) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Muscle Invasive Bladder Cancer (MIBC) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Muscle Invasive Bladder Cancer (MIBC) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Muscle Invasive Bladder Cancer (MIBC) (Oncology)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001492636/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Muscle Invasive Bladder Cancer (MIBC) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Argos Therapeutics Inc
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Cold Genesys Inc
F. Hoffmann-La Roche Ltd
MedImmune LLC
Oncolytics Biotech Inc
Sillajen Biotherapeutics
Taris Biomedical LLC
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001492636/discount
List of Tables
Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC), H2 2016 8
Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC) - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Argos Therapeutics Inc, H2 2016 17
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Astellas Pharma Inc, H2 2016 18
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Astex Pharmaceuticals Inc, H2 2016 19
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by AstraZeneca Plc, H2 2016 20
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Cold Genesys Inc, H2 2016 21
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 22
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by MedImmune LLC, H2 2016 23
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Oncolytics Biotech Inc, H2 2016 24
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Sillajen Biotherapeutics, H2 2016 25
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Taris Biomedical LLC, H2 2016 26
Assessment by Monotherapy Products, H2 2016 27
Assessment by Combination Products, H2 2016 28
Number of Products by Stage and Target, H2 2016 30
Number of Products by Stage and Mechanism of Action, H2 2016 32
Number of Products by Stage and Route of Administration, H2 2016 34
Number of Products by Stage and Molecule Type, H2 2016 36
Muscle Invasive Bladder Cancer (MIBC) - Dormant Projects, H2 2016 104Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC), H2 2016 8
Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC) - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Argos Therapeutics Inc, H2 2016 17
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Astellas Pharma Inc, H2 2016 18
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Astex Pharmaceuticals Inc, H2 2016 19
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by AstraZeneca Plc, H2 2016 20
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Cold Genesys Inc, H2 2016 21
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 22
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by MedImmune LLC, H2 2016 23
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Oncolytics Biotech Inc, H2 2016 24
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Sillajen Biotherapeutics, H2 2016 25
Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Taris Biomedical LLC, H2 2016 26
Assessment by Monotherapy Products, H2 2016 27
Assessment by Combination Products, H2 2016 28
Number of Products by Stage and Target, H2 2016 30
Number of Products by Stage and Mechanism of Action, H2 2016 32
Number of Products by Stage and Route of Administration, H2 2016 34
Number of Products by Stage and Molecule Type, H2 2016 36
Muscle Invasive Bladder Cancer (MIBC) - Dormant Projects, H2 2016 104
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001492636/buy/2000
Contact Information:
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results